A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Hyperlipidemia

In brief

The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.

Key facts

Study ID
NCT07229937
Run by
Shandong Suncadia Medicine Co., Ltd.
People needed
189
Starts
2025-11-25
Expected to finish
2026-08-01
Last updated by the study team
2025-12-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.